biosimilars

Insurance, physician barriers impede wider adoption of biosimilars
Insurance, physician barriers impede wider adoption of biosimilars
RAPS.org
biosimilars
physicians
insurance
Flag link:
Biogen adds a late-stage prospect to its growing biosimilar business
Biogen adds a late-stage prospect to its growing biosimilar business
BioPharma Dive
Biogen
Actemra
anti-inflammatories
biosimilars
COVID-19
Flag link:
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics
Pfizer halts biosimilar programs in crowded China market, sells plant to WuXi Biologics
Fierce Pharma
Pfizer
China
biosimilars
WuXi Biologics
Flag link:
Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality
Generics companies face risk as SCOTUS questions patent tribunal’s constitutionality
MedCity News
generics
Supreme Court
patents
biosimilars
devices
Flag link:
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Drug Patent Watch
regulatory
biosimilars
Europe
EMA
FDA
Flag link:
The More You Know: FDA Provides Additional Guidance on Biosimilars
The More You Know: FDA Provides Additional Guidance on Biosimilars
FDA Law Blog
FDA
biosimilars
Flag link:
Roche yields to cancer biosim competition by offering 'relevant' discounts: report
Roche yields to cancer biosim competition by offering 'relevant' discounts: report
Fierce Pharma
Roche
biosimilars
CMS
discounts
buy-and-bill
Flag link:
Samsung Biologics, AstraZeneca to dissolve biosimilar JV, scrap Rituxan copy program: report
Samsung Biologics, AstraZeneca to dissolve biosimilar JV, scrap Rituxan copy program: report
Fierce Pharma
Samsung BioLogics
AstraZeneca
Rituxan
Roche
biosimilars
Archigen Biotech
Flag link:
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilar
Pharmaforum
Novartis
Genentech
Lucentis
biosimilars
Samsung Bioepis
Biogen
FDA
Flag link:
Testing requirements are likely slowing biosimilar entries in the US
Testing requirements are likely slowing biosimilar entries in the US
RAPS.org
biosimilars
regulatory
patents
drug rebates
Flag link:
Sandoz working to overcome barriers to greater biosimilars uptake in US
Sandoz working to overcome barriers to greater biosimilars uptake in US
Biopharma Reporter
Sandoz
biosimilars
Novartis
Flag link:
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Biocon and Mylan Launch Semglee; Biosimilar, Interchangeable Status Are Sought
Center for Biosimilars
Biocon
Mylan
Semglee
generics
insulin
diabetes
biosimilars
Flag link:
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Pfizer's Unheralded Franchise That's Worth Billions of Dollars
Motley Fool
Pfizer
biosimilars
Humira
Inflectra
Remsima
Remicade
autoimmune disease
JNJ
Flag link:
Amgen's Enbrel Patents to Be Upheld Through 2029
Amgen's Enbrel Patents to Be Upheld Through 2029
Motley Fool
psoriasis
rheumatoid arthritis
Enbrel
Novartis
biosimilars
patents
Flag link:
AbbVie's Humira defense may keep prices high, but it's still legal, judge rules
AbbVie's Humira defense may keep prices high, but it's still legal, judge rules
Fierce Pharma
AbbVie
Humira
biosimilars
patents
Flag link:
Most big commercial health plans rarely prefer biosimilars
Most big commercial health plans rarely prefer biosimilars
Beckers Hospital Review
insurers
biosimilars
Flag link:
COVID-19 restrictions send generic drug shipping costs through the roof: survey
COVID-19 restrictions send generic drug shipping costs through the roof: survey
Fierce Pharma
COVID-19
generics
biosimilars
drug manufacturing
Flag link:
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Pharmaforum
Amgen
Allergan
biosimilars
Roche
rituximab
Flag link:
Biosimilar sales to reach $6.5B by 2024, study says
Biosimilar sales to reach $6.5B by 2024, study says
Beckers Hospital Review
biosimilars
Flag link:
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says
BioSpace
biosimilars
Amgen
Allergan
Roche
Rituxan
Bristol-Myers Squibb
ozanimod
risdiplam
Biomarin
valrox
Flag link:

Pages